Pharma's AI opportunity with AJ Rollsy at HealthPoint Research

Leading with empathy, with David Henderson at Takeda

Send us Fan Mail [https://www.buzzsprout.com/2551655/fan_mail/new] Future pharma host, Romain Bonjean, CEO of RoseRx, sits down with David Henderson [https://www.linkedin.com/in/david-henderson-3776b415/], Franchise Head Specialty Oceania at Takeda, who brings over 20 years of biopharmaceutical leadership experience including 13 years at Biogen where he rose to Managing Director for Australia and New Zealand. They explore what it means to lead with empathy in a digital age, how leadership approaches shift across international markets, and the cultural shifts toward personalized healthcare and patient segmentation. David discusses his bold call for Medical Affairs to move beyond the "zone of science" and become "agents of change," the ongoing tension between Medical Affairs and commercial teams and whether AI can help bridge that gap or fundamentally change what the job actually is. He also shares insights on the risks of over-segmentation, what keeps him up at night about the industry's future, and advice for new leaders navigating healthcare's rapid transformation.

From crawl to run: The reality of AI implementation in pharma with Arthur Alston

Send us Fan Mail [https://www.buzzsprout.com/2551655/fan_mail/new] Future pharma host, Romain Bonjean, CEO of RoseRx [https://www.linkedin.com/in/romainbonjean/], sits down with Arthur Alston [https://www.linkedin.com/in/arthuralston/], Head of Solid Tumours and Radioligand Therapy at Novartis Australia and New Zealand, who brings over 25 years of life sciences experience as both a trained physician and commercial leader.  They explore Arthur's "Crawl, Walk, Run" framework for AI adoption, why most pharma companies are still crawling despite buying licenses and the brutal realities of moving from enthusiasm to actual implementation. Arthur shares practical insights on building AI agents across multiple functions, the limitations of RAG architecture in pharma, navigating regulatory compliance in pharmacovigilance and where executives are actually seeing ROI. He also addresses the biggest mistakes companies make, why company policy might be your biggest barrier, and where AI can genuinely reduce administrative burden to help healthcare professionals focus on patient care.

Pharma’s next era with Josie Downey at Merck Healthcare ANZ

Send us Fan Mail [https://www.buzzsprout.com/2551655/fan_mail/new] ‘Not intended for US or Canadian viewers’. Future pharma host, Romain Bonjean, CEO of RoseRx, sits down with Josie Downey [https://www.linkedin.com/in/josie-downey/], Managing Director of Merck Healthcare Australia and New Zealand, who brings 25 years of pharmaceutical experience, having successfully established businesses across APAC and launching life changing iconic brands. She is driven to improve the lives of patients through a relentless pursuit of solving access challenges to ensure that no patient is left behind. They explore the difference between precision and personalised medicine, and confront the uncomfortable reality that Australians only have reimbursed access to 27% of new innovative medicines worldwide, with over 10,000 patients paying out of pocket for cancer treatments.  Josie discusses why the PBS is not fit for purpose in the era of precision medicine, the ethical dilemma of running clinical trials without guaranteed post-trial access, and Merck's partnership with Omico that's tripling their oncology trial programme through genomic profiling. They also dive into Merck's sophisticated AI adoption, ranked #2 globally among biopharma companies, analysing 700 billion rows of data, the ongoing debate about whether patients [https://www.roserx.health/patient-engagement-platform?utm_source=buzzsprout&utm_medium=link&utm_campaign=podcast-merck] or HCPs [https://www.roserx.health/hcp-engagement-platform?utm_source=buzzsprout&utm_medium=link&utm_campaign=podcast-merck] are the true customer, and why digital bioethics matters more than ever.

AI, privacy and the red line in healthcare with Phil O'Sullivan at Allens

Send us Fan Mail [https://www.buzzsprout.com/2551655/fan_mail/new] This episode of future pharma tackles the fast-evolving world of privacy, regulation and AI in healthcare with Phil O’Sullivan, partner at commercial law firm Allens. Phil explains how Australia’s principles-based Privacy Act is shifting, with much tougher penalties (including percentages of turnover) and growing expectations around governance, transparency, and use of patient data, especially as AI and LLMs move deeper into clinical support and patient-facing tools. He draws a clear “red line” where technology starts to replace, rather than simply assist, clinicians and unpacks what that means for liability, innovation and product design in life sciences. Throughout, he comes back to one core idea: organisations that want to innovate with AI and data need to operate above bare legal minimums, building trust through clear communication, strong safeguards and a realistic view of risk.

Pharma's AI opportunity with AJ Rollsy at HealthPoint Research

Send us Fan Mail [https://www.buzzsprout.com/2551655/fan_mail/new] Future pharma host, Romain Bonjean, CEO of RoseRx [https://www.roserx.health/?utm_source=buzzsprout&utm_medium=podcast&utm_campaign=podcast-1], sits down with AJ Rollsy, founder and Managing Director of HealthPoint Research [https://www.healthpointresearch.com/], who brings 25 years of global pharma and sales experience. They explore how AI is reshaping patient [https://www.roserx.health/compass-patient-engagement-platform?utm_source=buzzsprout&utm_medium=podcast&utm_campaign=podcast-1] and HCP engagement [https://www.roserx.health/compass-hcp-engagement-platform?utm_source=buzzsprout&utm_medium=podcast&utm_campaign=podcast-1], the tension between innovation and governance, the emotional and behavioural drivers behind health decisions and what pharma can learn from other industries, using examples from GLP-1 weight management, DTC models and global market nuances. AJ also shares where he thinks AI will genuinely add value for clinicians by reducing admin burden and helping them get back to what matters most: caring for patients.